Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous formulation, explained Sun Lim Min, MD, PhD.
Sun Lim Min, MD, PhD
Advertisement
Articles by Sun Lim Min, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
2
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
3
FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer
4
Science Under Attack: Experts Warn of Rising Threats to Research Integrity
5
